Table 2.

Patients with hematological neoplasms vs matched controls

No. of patientsCOVID-19 outcomePatients affected, NControls affected, NRelative riskConfidence interval
All patients with
hematological neoplasms (n = 32 156) 
Infection 106 64 1.60 1.12-2.37 
Symptomatic 68 35 1.72 1.05-2.85 
Hospitalized 50 15 3.13 1.68-7.08 
Severe 40 17 2.27 1.18-5.19 
Death 23 13 1.66 0.72-4.47 
Patients on treatment
(n = 5107) 
Infection 37 2.74 1.31-8.99 
Symptomatic 27 3.09 1.20-20.81 
Hospitalized 22 10.81 3.80-41.78 
Severe 19 8.97 3.13-35.07 
Death 13 19.31 3.95-30.72 
Patients without treatment
(n = 27 049) 
Infection 78 55 1.38 0.93-2.15 
Symptomatic 46 31 1.29 0.76-2.28 
Hospitalized 30 14 1.97 0.97-4.61 
Severe 23 14 1.66 0.70-4.00 
Death 12 11 1.40 0.43-4.49 
No. of patientsCOVID-19 outcomePatients affected, NControls affected, NRelative riskConfidence interval
All patients with
hematological neoplasms (n = 32 156) 
Infection 106 64 1.60 1.12-2.37 
Symptomatic 68 35 1.72 1.05-2.85 
Hospitalized 50 15 3.13 1.68-7.08 
Severe 40 17 2.27 1.18-5.19 
Death 23 13 1.66 0.72-4.47 
Patients on treatment
(n = 5107) 
Infection 37 2.74 1.31-8.99 
Symptomatic 27 3.09 1.20-20.81 
Hospitalized 22 10.81 3.80-41.78 
Severe 19 8.97 3.13-35.07 
Death 13 19.31 3.95-30.72 
Patients without treatment
(n = 27 049) 
Infection 78 55 1.38 0.93-2.15 
Symptomatic 46 31 1.29 0.76-2.28 
Hospitalized 30 14 1.97 0.97-4.61 
Severe 23 14 1.66 0.70-4.00 
Death 12 11 1.40 0.43-4.49 

or Create an Account

Close Modal
Close Modal